SBRT Then Pembrolizumab: Well Tolerated in Met Tumors

The significant tumor shrinkage and immunologic changes observed support a complementary role of SBRT and PD-1 immunotherapy, investigators concluded.

Source: CancerNetwork - February 23, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Immuno Oncology Radiation Oncology Source Type: news